GNI Group saw no growth in patent filings and highest growth of 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of GNI Group’s patent filings and grants. Buy the databook here.
GNI Group has been focused on protecting inventions in Israel(IL) with one publication in Q2 2024
The Israel(IL) Patent Office dominates the patent grants with nearly 100% of grants. The Israel(IL) patent Office are among the top ten patent offices where GNI Group is filings its patents. Among the top granted patent authorities, GNI Group has 100% of its grants in Israel(IL).
Immatics and Roche could be the strongest competitors for GNI Group
Stroke related patents lead GNI Group portfolio followed by myocardial infarction, and delayed graft function (dgf)
GNI Group has highest number of patents in stroke followed by myocardial infarction, delayed graft function (dgf), sepsis, and diabetic retinopathy.
For comprehensive analysis of GNI Group's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.